Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
D&D Pharmatech Inc. has 2 pending office actions distributed across the Biotechnology & Pharmaceuticals sector. These actions are split between 2 distinct examiners, showing that the company is navigating multiple perspectives within the patent office. Furthermore, the prosecution is occurring in 2 distinct art units, which implies a diversification of the company's technical claims or applications. This distribution across 2 distinct examiners and 2 distinct art units suggests a broad approach to their current pharmaceutical filings.
NIEBAUER, RONALD T serves as the busiest examiner with 1 busiest examiner pending action. Because the total number of pending office actions is 2, this examiner is responsible for 1 of the 2 current actions. Practitioners should note that the workload is evenly distributed, as no single examiner or art unit dominates the pending portfolio beyond the 1 busiest examiner pending action assigned to NIEBAUER, RONALD T. With 2 distinct examiners involved, the company must manage separate prosecution timelines. The presence of 2 distinct art units further indicates that the company is engaging with different specialized groups at the USPTO.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| JARRELL, NOBLE E | 1 | 81.1% | +9.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17615504 | PHYSIOLOGICALLY ACTIVE SUBSTANCE BOUND TO BIOTIN MOIETY, AND COMPOSITION FOR ORAL ADMINISTRATION INCLUDING SAME | JARRELL, NOBLE E | 56d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18690140 | PHARMACEUTICAL COMPOSITION COMPRISING LARGE PHYSIOLOGICALLY ACTIVE SUBSTANCE AND EXCIPIENT | NIEBAUER, RONALD T | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18690140 | PHARMACEUTICAL COMPOSITION COMPRISING LARGE PHYSIOLOGICALLY ACTIVE SUBSTANCE AND EXCIPIENT | NIEBAUER, RONALD T | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18690140 | PHARMACEUTICAL COMPOSITION COMPRISING LARGE PHYSIOLOGICALLY ACTIVE SUBSTANCE AND EXCIPIENT | NIEBAUER, RONALD T | 1612 | §101§102§103§112DP | Non-Final OA | — | Pending | Mar 07, 2024 |
| 17615504 | PHYSIOLOGICALLY ACTIVE SUBSTANCE BOUND TO BIOTIN MOIETY, AND COMPOSITION FOR ORAL ADMINISTRATION INCLUDING SAME | JARRELL, NOBLE E | 1699 | §112DP | Final Rejection | 56d | Pending | Nov 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial